Core Insights - CytomX Therapeutics reported disappointing financial results for Q4 and full-year 2025, missing revenue estimates significantly [2][3][4] Financial Performance - For Q4 2025, the company reported an adjusted loss of $0.22 per share, missing the Zacks estimate of a $0.08 loss, representing a 175% earnings surprise [3][6] - Revenue for Q4 was $0.66 million, a sharp decline from $38.09 million in the same quarter last year, primarily due to the completion of major collaborations and slower revenue recognition from partners [3][4] - Full-year 2025 revenue was $76.2 million, down approximately 44.8% from $138.1 million in 2024 [4] Financial Health - The company ended 2025 with $137.1 million in cash, cash equivalents, and investments, providing a runway into Q2 2027 [4] - CytomX has a strong liquidity position with a current ratio of 3.64 and a low debt-to-equity ratio of 5.21%, with total debt around $5.6 million [6] Pipeline and Future Outlook - Despite revenue challenges, the company is advancing its pipeline, including Varsetatug Masetecan and CX-801, with ongoing clinical data expected [4][5] - The stock reacted positively post-release, indicating some investor confidence in the company's future prospects [5]